Education
About Us
Working with TipRanks
Follow Us
MoonLake Immunotherapeutics (MLTX)
NASDAQ:MLTX
MLTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$31.42 - $58.26
Previous CloseN/A
Volume45.38K
Average Volume (3M)486.09K
Market Cap
$3.43B
Enterprise Value$2.64B
Total Cash (Recent Filing)$480.13M
Total Debt (Recent Filing)$75.60M
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Nov 18, 2025EPS Estimate
-0.86Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.87
Shares Outstanding63,474,255
10 Day Avg. Volume588,075
30 Day Avg. Volume486,089
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)7.62
Price to Sales (P/S)0.00
P/FCF Ratio-29.07
Enterprise Value/Market Cap0.77
Enterprise Value/Revenue25.94K
Enterprise Value/Gross Profit115.80K
Enterprise Value/Ebitda-22.26
Forecast
1Y Price Target
$77.00Price Target Upside44.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe release of top-line data from the Phase 3 VELA program with lead candidate sonelokimab (SLK) in hidradenitis suppurativa (HS) is considered a crucial potential catalyst for the company.
Financial ResourcesMoonLake has significant financial resources with cash, cash equivalents, and short-term marketable debt securities totaling approximately $425M and access to an additional $425M through a debt facility.
Market PositioningIf the VELA data demonstrate clear superiority of SLK to bimekizumab, MoonLake could be well-positioned to seize pole position in the HS indication and become a highly appealing M&A target.
Bears Say
Financial PerformanceMoonLake recorded a 2Q25 net loss of $0.87 per share, which was higher than the forecasted net loss of $0.76 per share, mainly due to higher-than-forecast R&D expenditures.
R&D ExpendituresThe higher-than-forecast R&D expenditures led to a greater net loss, which could be a concern for investors assessing the company's financial health.
MoonLake Immunotherapeutics News
MLTX FAQ
What was MoonLake Immunotherapeutics’s price range in the past 12 months?
MoonLake Immunotherapeutics lowest stock price was $31.42 and its highest was $58.26 in the past 12 months.
What is MoonLake Immunotherapeutics’s market cap?
MoonLake Immunotherapeutics’s market cap is $3.43B.
When is MoonLake Immunotherapeutics’s upcoming earnings report date?
MoonLake Immunotherapeutics’s upcoming earnings report date is Nov 18, 2025 which is in 96 days.
How were MoonLake Immunotherapeutics’s earnings last quarter?
MoonLake Immunotherapeutics released its earnings results on Aug 05, 2025. The company reported -$0.87 earnings per share for the quarter, missing the consensus estimate of -$0.74 by -$0.13.
Is MoonLake Immunotherapeutics overvalued?
According to Wall Street analysts MoonLake Immunotherapeutics’s price is currently Undervalued.
Does MoonLake Immunotherapeutics pay dividends?
MoonLake Immunotherapeutics does not currently pay dividends.
What is MoonLake Immunotherapeutics’s EPS estimate?
MoonLake Immunotherapeutics’s EPS estimate is -0.86.
How many shares outstanding does MoonLake Immunotherapeutics have?
MoonLake Immunotherapeutics has 63,474,255 shares outstanding.
What happened to MoonLake Immunotherapeutics’s price movement after its last earnings report?
MoonLake Immunotherapeutics reported an EPS of -$0.87 in its last earnings report, missing expectations of -$0.74. Following the earnings report the stock price went up 0.169%.
Which hedge fund is a major shareholder of MoonLake Immunotherapeutics?
Currently, no hedge funds are holding shares in MLTX
MoonLake Immunotherapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$77.00 (44.25% Upside)
$77.00 (44.25% Upside)
Blogger Sentiment
Bullish
MLTX Sentiment 66%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 113.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.8%
Last 30 Days ▲ 5.7%
Last 30 Days ▲ 5.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
20.63%
12-Months-Change
Fundamentals
Return on Equity
-40.29%
Trailing 12-Months
Asset Growth
-15.56%
Trailing 12-Months
Company Description
MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
MLTX Stock 12 Month Forecast
Average Price Target
$77.00
▲(44.25% Upside)
Technical Analysis
Amicus
―
ImmunityBio
―
Apellis Pharmaceuticals
―
Crinetics Pharmaceuticals
―
Immunovant
―
Ownership Overview
41.86% Insiders
17.69% Mutual Funds
0.21% Other Institutional Investors
39.56% Public Companies and
Individual Investors